Get the Stockscreener App
15.19
4.11%
0.60
Pre-market:
15.15
-0.04
-0.26%
Amylyx Pharmaceuticals Inc stock is traded at $15.19, with a volume of 2.90M.
It is up +4.11% in the last 24 hours and up +14.34% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
See More
Previous Close:
$14.59
Open:
$14.79
24h Volume:
2.90M
Relative Volume:
2.49
Market Cap:
$1.69B
Revenue:
$-665.00K
Net Income/Loss:
$-150.11M
P/E Ratio:
-10.08
EPS:
-1.5071
Net Cash Flow:
$-124.53M
1W Performance:
+16.76%
1M Performance:
+14.34%
6M Performance:
+20.94%
1Y Performance:
+175.18%
1-Day Range:
$14.69
$16.08
1-Week Range:
$13.08
$16.08
52-Week Range:
$4.80
$18.61
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Phone
617-682-0917
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
15.19 | 1.69B | -665.00K | -150.11M | -124.53M | -1.5071 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-26 | Initiated | Stifel | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Guggenheim | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape - Yahoo Finance
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026 - BioSpace
Amylyx (NASDAQ: AMLX) director receives 24,372 stock options grant - Stock Titan
Amylyx (AMLX) director Karen Firestone receives 24,372 stock options grant - Stock Titan
Amylyx (NASDAQ: AMLX) director receives 24,372-share stock option grant - Stock Titan
Amylyx (NASDAQ: AMLX) director awarded 24,372 stock options at $14.31 strike - Stock Titan
Amylyx (AMLX) director Paul Fonteyne receives grant of 24,372 stock options - Stock Titan
Claim your share of the $6.5M Amylyx Pharmaceuticals securities class action settlement - Claim Depot
Post-bariatric hypoglycemia toll, avexitide trial design at ENDO 2026 - Stock Titan
H.C. Wainwright reiterates Amylyx stock rating on PBH trial insights By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Amylyx stock rating on PBH trial insights - Investing.com
Amylyx earnings on deck ahead of pivotal avexitide trial data By Investing.com - Investing.com Nigeria
Amylyx Pharmaceuticals eyes phase 3 AVEXITIDE readout as 2027 launch comes into focus - MSN
Amylyx Pharmaceuticals (NASDAQ: AMLX) investors approve directors, auditor and say-on-pay - Stock Titan
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Its Recent Share Price Rebound - Yahoo Finance
AMLX Stock Price, Quote & Chart | AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX) - ChartMill
Amylyx Pharmaceuticals (AMLX) Gains 3.36% as Shares Approach ResistanceWatchlist Stock Ideas - thelegaladvocate.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX) - The Globe and Mail
Amylyx director Karen Firestone purchases $51,338 of common stock. By Investing.com - Investing.com Nigeria
Amylyx director Karen Firestone purchases $51,338 of common stock. - Investing.com
Director Karen Firestone adds Amylyx Pharmaceuticals (AMLX) shares - Stock Titan
Amylyx gets FDA fast track status for ALS treatment - MSN
Amylyx Pharmaceuticals (AMLX) Slips 2.5% as Biotech Sector Faces Renewed ScrutinyAAII Bullish - thelegaladvocate.com
Amylyx Stock: Why the Full Pipeline Story Matters - MarketBeat
Guggenheim Initiates Coverage of Amylyx Pharmaceuticals (AMLX) with Buy Recommendation - MSN
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer FRATES JAMES M - Moomoo
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 2026 Results and Pipeline Progress - Insider Monkey
Amylyx Pharmaceuticals, Inc.Common Stock (NQ: AMLX - FinancialContent
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation - BioSpace
Teva Pharmaceutical (TEVA) Reports Q1 Beat, Plans Amylyx Deal - Yahoo Finance
Number of shareholders of Amylyx Pharmaceuticals, Inc. – BOATS:AMLX - TradingView
Perceptive group holds 8.28M shares of Amylyx (AMLX) in Schedule 13G/A - Stock Titan
Amylyx publishes phase 2 Wolfram syndrome trial results - Investing.com
Amylyx publishes phase 2 Wolfram syndrome trial results By Investing.com - Investing.com Nigeria
Contributor: Fuel drug development, not Big Pharma's profits - AOL.com
B of A Securities Maintains Amylyx Pharmaceuticals (AMLX) Buy Recommendation - MSN
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):